Welcome to our dedicated page for Irhythm Technologies SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC documents from iRhythm Technologies don’t just recount earnings—they weave together reimbursement rulings, FDA study updates, and device-level production metrics that can shift Zio patch economics overnight. For investors, pulling the one sentence about CMS pricing from a 250-page 10-K or tracking day-to-day insider sales feels daunting.
Stock Titan solves that complexity. Our AI reads every iRhythm quarterly earnings report 10-Q filing, each iRhythm 8-K material event, and flags changes in plain English. Want iRhythm insider trading Form 4 transactions within minutes? You’ll see alerts the moment the Form 4 hits EDGAR, complete with contextual charts. Need an iRhythm annual report 10-K simplified or a quick iRhythm earnings report filing analysis? Our summaries spotlight Zio XT volume, average selling price shifts, and R&D spend so you can focus on decisions instead of footnotes.
Common investor questions are answered up front:
- iRhythm Form 4 insider transactions real-time
- iRhythm proxy statement executive compensation details
- understanding iRhythm SEC documents with AI
Beyond speed, our platform ties each disclosure to what truly moves the stock: hospital adoption rates, Medicare billing codes, and manufacturing scale. Drill into an iRhythm executive stock transactions Form 4 to see how trades align with new Zio AT rollouts, or compare segment margins across quarters without combing through PDFs. With real-time updates, complete filing coverage, and AI-powered plain-language explanations, iRhythm SEC filings explained simply becomes more than a promise—it’s the workflow that lets you act before the market does.
Shrishrimal Sumi, EVP and Chief Risk Officer of iRhythm Technologies (IRTC), reported a sale of company stock. The Form 4 shows a single non-derivative disposition of 653 shares of common stock on 08/22/2025 at a price of $167.12 per share, leaving the reporting person with 34,032 shares beneficially owned.
The filing states the sale was executed pursuant to a Rule 10b5-1 trading plan established by the reporting person on May 23, 2025. The Form 4 was filed by one reporting person and signed by an attorney-in-fact.
iRhythm Technologies, Inc. (IRTC) Form 144 notice: An individual proposes to sell 653 shares of Common stock on or about 08/22/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing reports an aggregate market value of $109,129.36 and total shares outstanding of 32,127,763. The seller previously sold 1,608 shares on 06/02/2025 for gross proceeds of $225,457.68. Acquisition details for the 653 shares show three lots: 400 restricted shares acquired 06/01/2024, 129 ESPP shares 05/31/2023, and 124 ESPP shares 11/30/2022.
Capital Research Global Investors filed Amendment No.4 to a Schedule 13G/A reporting its holdings in iRhythm Technologies, Inc. (Common Stock, CUSIP 450056106). The filing states CRGI holds 1,506,864 shares, representing 4.7% of the 31,925,267 shares believed outstanding, with sole voting and dispositive power for that amount. The filing cites an event date of 06/30/2025 and is signed on 08/05/2025.
The filing describes CRGI as a division of Capital Research and Management Company and related investment management entities that provide services under the name "Capital Research Global Investors." The statement includes a certification that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Marc Rosenbaum, Chief Accounting Officer of iRhythm Technologies (IRTC), sold 226 shares of the company's common stock on 08/11/2025 at a reported price of $158.93 per share.
The Form 4 states the sale was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on May 12, 2025. Following the reported transaction Rosenbaum beneficially owns 10,879 shares, held directly. The filing identifies his relationship to the issuer as an officer (Chief Accounting Officer) and discloses the transaction as a planned disposition under the 10b5-1 framework.
iRhythm Technologies director Abhijit Talwalkar executed a Rule 10b5-1 trading plan on August 11, 2025. He exercised employee stock options to acquire 5,312 shares at an exercise price of $10.71 and then sold those shares in two series: 3,183 shares at a weighted-average price of $157.5723 and 2,129 shares at a weighted-average price of $158.6792. The reported sale price ranges were $157.2350–$158.1800 and $158.3100–$159.0000. Following these transactions, his beneficial ownership is reported as 20,299 shares. The option exercised was originally granted May 23, 2016 and expires May 23, 2026.
The filing is a Form 144 for iRhythm Technologies (IRTC) reporting a proposed sale of 5,312 common shares with an aggregate market value of $839,380.46. The shares are listed for sale on NASDAQ with an approximate sale date of 08/11/2025 and the issuer's total shares outstanding are reported as 32,127,763.
The filer states the shares were acquired on 08/11/2025 by stock option exercise from the issuer, with payment in cash, and the proposed sale will be executed through Morgan Stanley Smith Barney LLC. The form indicates nothing to report for securities sold by the filer in the past three months and includes the filer's representation that they do not know of undisclosed material adverse information about the issuer.
Form 144 filed for iRhythm Technologies (IRTC) shows an insider intends to sell a small block of common stock through Morgan Stanley Smith Barney on NASDAQ. The notice specifies 226 shares with an aggregate market value of $35,918.18, acquired under the company Employee Stock Purchase Plan on 11/30/2023 and paid for in cash. The filer previously sold 696 shares on 06/02/2025 for $97,586.16. With 32,127,763 shares outstanding reported on the form, the planned sale represents approximately 0.0007% of the outstanding shares, indicating the transaction is immaterial to total equity. The filer certifies there is no undisclosed material adverse information and includes standard Rule 10b5-1 language if applicable.
FAQ
What is the current stock price of Irhythm Technologies (IRTC)?
What is the market cap of Irhythm Technologies (IRTC)?
